16 results about "Camptothecin Analog" patented technology

Described herein are anti-NaPi2b antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analog of Formula (I). The antibody construct of the ADC comprises an amino acid modification in the Fc that knocks out binding to Fc gamma receptors. The ADCs are useful as therapeutic agents, among others, in the treatment of cancer.

Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.

Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and / or derivatives. In certain embodiments, provided are specific and efficient methods for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition techniques. Camptothecin analogs, antibody-drug conjugates, and compositions which comprise glutaminyl-modified antibodies and camptothecin analog payloads and are provided.

The present disclosure relates to conjugates of camptothecin analogs of the formula T-(L-D) m with a cell binding molecule. The present disclosure also provides methods for preparing conjugates of camptothecin analogs with cell binding agents, and methods of using the conjugates in tumor-targeted therapy.

Camptothecin analogs of formula (I), (II), (III) are described, as well as conjugates comprising these camptothecin analogs. These camptothecin analogs and conjugates are useful as therapeutic agents, particularly for the treatment of cancer, infectious diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency diseases.

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analog of Formula (I). The ADCs are useful as therapeutic agents, particularly in the treatment of cancer.

Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, such as camptothecin analogs and / or derivatives. In certain embodiments, provided are specific and effective methods for producing protein-drug constructs (e.g., antibody-drug conjugates) using a combination of a transglutaminase and a 1, 3-cycloaddition technique. Provided are camptothecin analogs, antibody-drug conjugates, and compositions comprising a glutaminyl modified antibody and a camptothecin analog payload.

To provide an effective antibody-drug conjugate comprising an anti-FRα antibody, with high specificity, low toxicity (improved therapeutic index) and differentiated mechanism of action of the payload.SOLUTION: Provided is an antibody-drug conjugate in which the antibody specifically binds to folate receptor alpha (FRα) and in which the drug is selected from topoisomerase I inhibitors, camptothecin analogs such as exatecan. Such an antibody-drug conjugate is especially useful for treating proliferative diseases including cancers such as ovarian, breast or lung cancer.SELECTED DRAWING: None

Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the conjugates in targeted treating of cancer.

The present disclosure relates to conjugates of novel camptothecin analogs and cell-binding molecules of formula (I). Also provided are methods for preparing the conjugates of camptothecin analogs and cell-binding agents, and methods for applying the conjugates in targeted cancer therapy.

For example, protein-drug conjugates and compositions thereof useful for target-specific delivery of therapeutic moieties, such as camptothecin analogs and / or derivatives, are described herein. In certain embodiments, a specific and efficient method for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition technology is provided. Camptothecin analogs, antibody-drug conjugates, and compositions comprising glutaminyl-modified antibodies and camptothecin analog payloads are provided.

The invention provides novel camptothecin analogs and immunoconjugates thereof, as well as pharmaceutical compositions and methods of preparation and use for treating various diseases and disorders (e.g., cancer).

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human glypican 3 (GPC3) conjugated to a camptothecin analog of formula (I). The ADCs are useful as therapeutic agents, particularly in the treatment of cancer.

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents for use in increasing the sensitivity of tumors to the chemotherapeutic agents for use in treating cancers characterized by Nectin-4-expressing tumor cells. In one embodiment, the present invention provides conjugates of anti-Nectin-4 antibodies conjugated to camptothecin analogs such as exatecan or SN-38 via a cleavable linker.

The application discloses preparation of a kind of supermolecular nanoparticle self-assembled by polypeptide conjugated drug with stimulation response and application in brain tumor: polypeptide conjugate comprising a class of quinoline derivative analogs and camptothecin analogs.Quinoline derivative analogs and camptothecin analogs are connected on brain targeting peptide through sensitive peptide, and are further self-assembled to form supermolecular nanoparticle, improve the brain targeting ability and brain retention efficiency of drug.The polypeptide conjugated drug supermolecular nanoparticle provided in the application shows excellent ability of killing tumor cells and polarizing anti-inflammatory macrophages in vivo and in vitro, has strong inhibition effect on brain tumor, and has great clinical application value.